Oric Pharmaceuticals, Inc. (ORIC): Shareholders' Equity
$384.36M
As of 2025-12-31
$381.26M
As of 2026-06-30
+20.0%
3-year compound annual growth
+5.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $384.36M | +58.1% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $243.12M | +8.5% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $224.09M | +0.8% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $222.35M | -18.5% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $272.98M | -5.8% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $289.78M | n/m | 2022-03-21, Balance as of period end |
| 2019-12-31 | -$90.08M | n/m | 2022-03-21, Balance as of period end |
| 2018-12-31 | -$64.43M | n/a | 2021-03-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $384.36M | +58.1% |
| Alumis Inc. (ALMS) | 2025-12-31 | $301.30M | +15.8% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $312.32M | -23.4% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $352.46M | +53.9% |
| Harrow, Inc. (HROW) | 2025-12-31 | $52.45M | -24.7% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $346.18M | +73.5% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | -$261.83M | n/m |
| Erasca, Inc. (ERAS) | 2025-12-31 | $325.17M | -23.2% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $304.48M | -31.9% |
Compare ORIC, ALMS, NKTX, STOK side by side · Screen every company in Pharmaceutical Preparations ↗